SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
Hercules Capital(HTGC) Prnewswire·2024-04-30 07:00SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody Provides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation Funding is additional to recent $75m Series B financing DUBLIN and OXFORD, England, April 30, 2024 /PRNewswire/ -- SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the ...